中国肺癌的驱动基因研究进展

doi:10.3981/j.issn.1000-7857.2014.26.005

摘要
图/表
参考文献
相关文章 (4)

全文: PDF (524 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要肺癌是中国发病率及死亡率最高的恶性肿瘤。肿瘤细胞在驱动基因的作用下持续生长，并对该驱动基因的抑制剂具有高敏感性。近年来，针对驱动基因的检测技术不断发展，相应的驱动基因靶向药物也层出不穷。本文主要从中国肺癌的驱动基因、驱动基因的检测及针对驱动基因的靶向治疗3 个方面进行综述，并展望中国肺癌驱动基因的应用前景。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	钱晓燕
	石远凯
	韩晓红

关键词 ：肺癌, 驱动基因, 靶向治疗

Abstract：Lung cancer is the leading morbidity and mortality malignant tumor in China. Cancer cells keep growing under the action of driver genes and are sensitive to driver gene inhibitors. Recent years have witnessed continuous developments of driver gene detection technology and driver gene-targeted drugs. This review focus on the driver genes in lung cancer, detection of driver genes and targeted therapy of driver genes, giving a glimpse of the application prospect of driver genes for Chinese patients with lung cancer.

Key words： lung cancer driver genes targeted therapy

收稿日期: 2014-08-12

ZTFLH:

R734.2

基金资助:国家高技术研究发展计划（863计划）项目（2011AA02A110）；国家重大新药创制科技重大专项（2012ZX09303012）；国家自然科学基金项目（81372384）；北京市自然科学基金项目（7141010），北京市科委重大项目（D141100000214003）

通讯作者: 韩晓红，研究员，研究方向为抗肿瘤药物疗效评价及预后相关的分子标志物，电子信箱：hanxh@cicams.ac.cn；xiaohonghan@hotmail.com E-mail: hanxh@cicams.ac.cn；xiaohonghan@hotmail.com

作者简介: 钱晓燕，硕士研究生，研究方向为肿瘤分子标志物，电子信箱：qianxiaoyan2012@163.com

引用本文:

钱晓燕, 石远凯, 韩晓红. 中国肺癌的驱动基因研究进展[J]. 科技导报, 2014, 32(26): 42-46.
QIAN Xiaoyan, SHI Yuankai, HAN Xiaohong. Recent Advances in the Study of Driver Genes for Chinese Lung Cancer. journal1, 2014, 32(26): 42-46.

链接本文:

http://www.kjdb.org/CN/10.3981/j.issn.1000-7857.2014.26.005 或 http://www.kjdb.org/CN/Y2014/V32/I26/42

[1] Chen W, Zheng R, Zhang S, et al. Annual report on status of cancer in China, 2010[J]. Chinese Journal of Cancer Research, 2014, 26(1): 48- 58.
[2] Weinstein I B. Addiction to oncogenes——the Achilles heal of cancer[J]. Science, 2002, 297(5578): 63-64.
[3] Sharma S V, Gajowniczek P, Way I P, et al. A common signaling cascade may underlie "addiction" to the Src, BCR-ABL, and EGF receptor oncogenes[J]. Cancer Cell, 2006, 10(5): 425-435.
[4] Irmer D, Funk J O, Blaukat A. EGFR kinase domain mutations-functional impact and relevance for lung cancer therapy[J]. Oncogene, 2007, 26(39): 5693-5701.
[5] Dutta P R, Maity A. Cellular responses to EGFR inhibitors and their relevance to cancer therapy[J]. Cancer Letters, 2007, 254(2): 165-177.
[6] Chan S K, Gullick W J, Hill M E. Mutations of the epidermal growth factor receptor in non-small cell lung cancer-search and destroy[J]. European Journal of Cancer, 2006, 42(1): 17-23.
[7] Yatabe Y. EGFR mutations and the terminal respiratory unit[J]. Cancer and Metastasis Reviews, 2010, 29(1): 23-36.
[8] Kris M G, Johnson B E, Kwiatkowski D J, et al. Identification of driver mutations in tumor specimens from 1000 patients with lung adenocarcinoma: The NCI's Lung Cancer Mutation Consortium (LCMC)[J]. Journal of Clinical Oncology, 2011, 29(S18): CRA7506.
[9] Shi Y, Au J S K, Thongprasert S, et al. A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced nonsmall- cell lung cancer of Adenocarcinoma Histology (PIONEER) [J]. Journal of Thoracic Oncology, 2014, 9(2): 154-162.
[10] Soda M, Choi Y L, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer[J]. Nature, 2007, 448(7153): 561-566.
[11] Wong D W S, Leung E L H, So K K T, et al. The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS[J]. Cancer, 2009, 115(8): 1723-1733.
[12] Zhang X, Zhang S, Yang X, et al. Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression[J]. Molecular Cancer, 2010, 9(1): 188-199.
[13] Li H, Pan Y, Li Y, et al. Frequency of well-identified oncogenic driver mutations in lung adenocarcinoma of smokers varies with histological subtypes and graduated smoking dose[J]. Lung Cancer, 2013, 79 (1): 8-13.
[14] Mitsudomi T, Suda K, Tomizawa K, et al. Clinico-pathologic features of lung cancer with EML4-ALK translocation[C]//ASCO Annual Meeting Proceedings. 2010, 28(S15): 10598.
[15] Rodig S J, Mino-Kenudson M, Dacic S, et al. Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population[J]. Clinical Cancer Research, 2009, 15(16): 5216- 5223.
[16] Rikova K, Guo A, Zeng Q, et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer[J]. Cell, 2007, 131 (6): 1190-1203.
[17] Bergethon K, Shaw A T, Ou S H I, et al. ROS1 rearrangements define a unique molecular class of lung cancers[J]. Journal of Clinical Oncology, 2012, 30(8): 863-870.
[18] Li C, Fang R, Sun Y, et al. Spectrum of oncogenic driver mutations in lung adenocarcinomas from East Asian never smokers[J]. PLoS One, 2011, 6(11): e28204.
[19] Cai W, Li X, Su C, et al. ROS1 fusions in Chinese patients with nonsmall- cell lung cancer[J]. Annals of Oncology, 2013, 24(7): 1822- 1827.
[20] Gao B, Sun Y, Zhang J, et al. Spectrum of LKB1, EGFR, and KRAS mutations in Chinese lung adenocarcinomas[J]. Journal of Thoracic Oncology: Official Publication of the International Association for the Study of Lung Cancer, 2010, 5(8): 1130.
[21] 邱田, 凌云, 陈钊, 等. 荧光PCR-优化寡核苷酸探针法与Sanger 测序法检测肺癌, 结直肠癌患者KRAS 基因突变的对比分析[J]. 中华病理学杂志, 2012, 41(9): 599-602. Qiu Tian, Ling Yun, Chen Zhao, et al. Comparison of real-time PCRoptimized oligonucleotide probe method and Sanger sequencing for detection of KRAS mutations in colorectal and lung carcinomas[J]. Chinese Journal of Pathology, 2012, 41(9): 599-602.
[22] Eberhard D A, Johnson B E, Amler L C, et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib[J]. Journal of Clinical Oncology, 2005, 23(25): 5900-5909.
[23] Mitsudomi T, Steinberg S M, Oie H K, et al. Ras gene mutations in non-small cell lung cancers are associated with shortened survival irrespective of treatment intent[J]. Cancer Research, 1991, 51(18): 4999-5002.
[24] Davies H, Bignell G R, Cox C, et al. Mutations of the BRAF gene in human cancer[J]. Nature, 2002, 417(6892): 949-954.
[25] Paumelle R, Tulasne D, Kherrouche Z, et al. Hepatocyte growth factor/scatter factor activates the ETS1 transcription factor by a RAS-RAFMEK- ERK signaling pathway[J]. Oncogene, 2002, 21(15): 2309-2319.
[26] Ma P C, Jagadeeswaran R, Jagadeesh S, et al. Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer[J]. Cancer Research, 2005, 65(4): 1479-1488.
[27] Engelman J A, Zejnullahu K, Mitsudomi T, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling[J]. Science, 2007, 316(5827): 1039-1043.
[28] Bean J, Brennan C, Shih J Y, et al. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib[J]. Proceedings of the National Academy of Sciences, 2007, 104(52): 20932-20937.
[29] Weiss J, Sos M L, Seidel D, et al. Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer[J]. Science Translational Medicine, 2010, 2 (62): 62ra93-62ra93.
[30] Zhang J, Zhang L, Su X, et al. Translating the therapeutic potential of AZD4547 in FGFR1-amplified non-small cell lung cancer through the use of patient-derived tumor xenograft models[J]. Clinical Cancer Research, 2012, 18(24): 6658-6667.
[31] Peifer M, Fernández-Cuesta L, Sos M L, et al. Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer[J]. Nature Genetics, 2012, 44(10): 1104-1110.
[32] Steck P A, Pershouse M A, Jasser S A, et al. Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23. 3 that is mutated in multiple advanced cancers[J]. Nature Genetics, 1997, 15 (4): 356-362.
[33] Yokomizo A, Tindall D J, Drabkin H, et al. PTEN/MMAC1 mutations identified in small cell, but not in non-small cell lung cancers[J]. Oncogene, 1998, 17(4): 475-479.
[34] 张红蕊, 王晓红, 白淑平. PTEN和MDM2在非小细胞肺癌中的表达及临床意义[J]. 现代生物医学进展, 2011, 11(6): 1128-1131. Zhang Hongrui, Wang Xiaohong, Bai Shuping. The expression and clinical significance of PTEN and MDM2 in non-small cell lung cancer[J]. Progress in Modern Biomedicine, 2011, 11(6): 1128-1131.
[35] Sequist L V, Heist R S, Shaw A T, et al. Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice[J]. Annals of Oncology, 2011: 22(12): 2616-2624.
[36] Yamamoto H, Shigematsu H, Nomura M, et al. PIK3CA mutations and copy number gains in human lung cancers[J]. Cancer Research, 2008, 68(17): 6913-6921.
[37] Hammerman P S, Sos M L, Ramos A H, et al. Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer[J]. Cancer Discovery, 2011, 1(1): 78-89.
[38] Miao L, Wang Y, Zhu S, et al. Identification of novel driver mutations of the discoidin domain receptor 2 (DDR2) gene in squamous cell lung cancer of Chinese patients[J]. BMC Cancer, 2014, 14(1): 369.
[39] 梁智勇. 中国非小细胞肺癌患者表皮生长因子受体基因突变检测专家共识[J]. 中华病理学杂志, 2011, 40(10): 700-702. Liang Zhiyong. Expert consensus on epidermal growth factor receptor gene mutation detection in non-small cell lung cancer patients in China[J]. Chinese Journal of Pathology, 2011, 40(10): 700-702.
[40] 中国医师协会肿瘤医师分会, 中国抗癌协会肿瘤临床化疗专业委员会. 中国表皮生长因子受体基因突变和间变淋巴瘤激酶融合基因阳性非小细胞肺癌诊断治疗指南(2014版)[J]. 中华肿瘤杂志, 2014, 36 (7): 555-557. Cancer Doctors Branch of Chinese Medical Doctor Association, the Chinese Anti- Cancer Association Professional Committee of tumor chemotherapy. Guidelines about diagnosis and treatment on nonsmall cell lung cancer with epidermal growth factor receptor mutations and lymphoma kinase gene fusion positive in China (Version 2014)[J]. Chinese Journal of Oncology, 2014, 36(7): 555-557.
[41] Marchetti A, Del Grammastro M, Filice G, et al. Complex mutations & subpopulations of deletions at exon 19 of EGFR in NSCLC revealed by next generation sequencing: Potential clinical implications[J]. PloS One, 2012, 7(7): e42164.
[42] Liu P, Morrison C, Wang L, et al. Identification of somatic mutations in non-small cell lung carcinomas using whole-exome sequencing[J]. Carcinogenesis, 2012, 33(7): 1270-1276.
[43] Shi Y, Zhang L, Liu X, et al. Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): A randomised, double-blind phase 3 non-inferiority trial[J]. The Lancet Oncology, 2013, 14(10): 953-961.
[44] Shaw A T, Camidge D R, Engelman J A, et al. Clinical activity of crizotinib in advanced non-small cell lung cancer (NSCLC) harboring ROS1 gene rearrangement[C]//ASCO Meeting Abstracts, 2012, 30 (S15): 7508.
[45] Planchard D, Mazieres J, Riely G I, et al.Interim results of phase II study BRF113928 of dabrafenib in BRAF V600E mutation-positive non-small cell lung cancer（NSCLC）patients[J]. Journal of Clinical Oncology, 2013, 31(S1)：CRA7502.